drugset / Trial / NCT07127822
Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
Phase 2
Not yet recruiting
106 enrolled
Peking University
Peking University Cancer Hospital & Institute · collabQilu Pharmaceutical Co., Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
A randomized controlled phase II study exploring first-line treatment options for recurrent/metastatic MSI-H gastric cancer
Timeline
- Start
- 2025-09-01
- Primary completion
- 2027-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iparomlimab | Monoclonal antibody | — | — |
| Subject | Tuvonralimab | Monoclonal antibody | — | — |